Enzyme-linked Immunosorbent Assay Market Outlook:
Enzyme-linked Immunosorbent Assay Market size was over USD 2.64 billion in 2025 and is projected to reach USD 5.24 billion by 2035, growing at around 7.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of enzyme-linked immunosorbent assay is evaluated at USD 2.81 billion.
The growth of this sector can be primarily attributed to the increasing incidence of chronic diseases worldwide. Enzyme-linked immunosorbent assay plays a significant role in detecting, monitoring, and treating these health issues resulting in enhanced patient outcomes. The cases of chronic diseases globally are expected to grow by 57% by the end of 2025 report as per a report by the World Health Organization This escalating health crisis underscores the critical need for advanced diagnostic tools like ELISA in effectively managing and combating these ailments.
The development of enzyme immunoassays by major industry players contributes to the market's expansion. To identify IgA and IgM antibodies against four SARS-CoV-2 antigens, for example, Bio-Rad introduced the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels in September 2021. The multiplex immunoassay panels aided in the assessment of therapeutic efficacy by the vaccine developers during the development, clinical, and post-marketing phases.
